These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22616398)

  • 61. Beyond the lies: solving the problem.
    Morreim EH
    Am J Bioeth; 2004; 4(4):61-3. PubMed ID: 16192210
    [No Abstract]   [Full Text] [Related]  

  • 62. Health care rationing and professional integrity: not necessarily incompatible.
    White BC
    APA Newsl Philos Med; 1993; 92(1):80-5. PubMed ID: 12083100
    [No Abstract]   [Full Text] [Related]  

  • 63. Genetic enhancement, distributive justice, and the goals of medicine.
    Hall MA
    San Diego Law Rev; 2002; 39(3):669-81. PubMed ID: 15508227
    [No Abstract]   [Full Text] [Related]  

  • 64. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Marginal medicine.
    Lamm RD
    JAMA; 1998 Sep; 280(10):931-3. PubMed ID: 9739981
    [No Abstract]   [Full Text] [Related]  

  • 66. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 69. One drug to treat many diseases: unlocking the economic trap of rare diseases.
    Pierzynowska K; Kamińska T; Węgrzyn G
    Metab Brain Dis; 2020 Dec; 35(8):1237-1240. PubMed ID: 32926291
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Orphanage at the FDA.
    Chen E
    J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
    [No Abstract]   [Full Text] [Related]  

  • 72. Ethical and value issues in insurance coverage for cancer treatment.
    Brock DW
    Oncologist; 2010; 15 Suppl 1():36-42. PubMed ID: 20237216
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The ethics of insurance limiting institutional medical care: It's all about the money.
    Jones JW; McCullough LB
    J Vasc Surg; 2016 Apr; 63(4):1108-9. PubMed ID: 27016860
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Orphan economics: the downside of supplyside pharmacology.
    Samson K
    Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
    [No Abstract]   [Full Text] [Related]  

  • 75. Indecent coverage? Protecting the goals of health insurance from the impact of co-payments.
    Hurst SA; Danis M
    Camb Q Healthc Ethics; 2006; 15(1):107-13. PubMed ID: 16529313
    [No Abstract]   [Full Text] [Related]  

  • 76. Policymaking for Orphan Drugs and Its Challenges.
    Rhee TG
    AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879
    [No Abstract]   [Full Text] [Related]  

  • 77. Ranting in 2017: Is It Working?
    Hirsch IB
    Diabetes Technol Ther; 2017 Feb; 19(2):69-72. PubMed ID: 28080132
    [No Abstract]   [Full Text] [Related]  

  • 78. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
    Degtiar I
    Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost of illness and economic evaluation in rare diseases.
    López-Bastida J; Oliva-Moreno J
    Adv Exp Med Biol; 2010; 686():273-82. PubMed ID: 20824451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.